>

Correlation Between Novo Nordisk and Bristol Myer

Analyzing existing cross correlation between Novo Nordisk AS and Bristol Myer Squi Pf. You can compare the effects of market volatilities on Novo Nordisk and Bristol Myer and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Novo Nordisk with a short position of Bristol Myer. Check out your portfolio center. Please also check ongoing floating volatility patterns of Novo Nordisk and Bristol Myer.

Specify exactly 2 symbols:

Refresh Compare

Diversification Opportunities for Novo Nordisk and Bristol Myer

Novo Nordisk AS diversification synergy
0.38
<div class='circular--portrait-small' style='background:#0D8ECF;color: white;font-size:1.1em;padding-top: 12px;;'>NOV</div>
<div class='circular--portrait-small' style='background:#0D52D1;color: white;font-size:1.1em;padding-top: 12px;;'>BMY</div>

Weak diversification

The 3 months correlation between Novo and Bristol is 0.38. Overlapping area represents the amount of risk that can be diversified away by holding Novo Nordisk AS and Bristol Myer Squi Pf in the same portfolio assuming nothing else is changed. The correlation between historical prices or returns on Bristol Myer Squi and Novo Nordisk is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Novo Nordisk AS are associated (or correlated) with Bristol Myer. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Bristol Myer Squi has no effect on the direction of Novo Nordisk i.e. Novo Nordisk and Bristol Myer go up and down completely randomly.

Pair Corralation between Novo Nordisk and Bristol Myer

Considering 30-days investment horizon, Novo Nordisk is expected to generate 2.65 times less return on investment than Bristol Myer. But when comparing it to its historical volatility, Novo Nordisk AS is 5.39 times less risky than Bristol Myer. It trades about 0.13 of its potential returns per unit of risk. Bristol Myer Squi Pf is currently generating about 0.06 of returns per unit of risk over similar time horizon. If you would invest  100,200  in Bristol Myer Squi Pf on January 25, 2020 and sell it today you would earn a total of  13,250  from holding Bristol Myer Squi Pf or generate 13.22% return on investment over 30 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy95.31%
ValuesDaily Returns

Novo Nordisk AS  vs.  Bristol Myer Squi Pf

 Performance (%) 
    
  Timeline 
Novo Nordisk AS 
88

Risk-Adjusted Performance

Compared to the overall equity markets, risk-adjusted returns on investments in Novo Nordisk AS are ranked lower than 8 (%) of all global equities and portfolios over the last 30 days. Allthough quite uncertain forward indicators, Novo Nordisk may actually be approaching a critical reversion point that can send shares even higher in March 2020.
Bristol Myer Squi 
44

Risk-Adjusted Performance

Compared to the overall equity markets, risk-adjusted returns on investments in Bristol Myer Squi Pf are ranked lower than 4 (%) of all global equities and portfolios over the last 30 days. Inspite very weak forward-looking indicators, Bristol Myer displayed solid returns over the last few months and may actually be approaching a breakup point.

Novo Nordisk and Bristol Myer Volatility Contrast

 Predicted Return Density 
    
  Returns 
Check out your portfolio center. Please also try Content Syndication module to quickly integrate customizable finance content to your own investment portal.